Order Article Reprints

Kouroukis CT, Crump M, MacDonald D, Larouche JF, Stewart DA, Johnston J, Sauvageau S, Beausoleil E, Sage P, Dubois SG, et al. An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. Current Oncology. 2015; 22(4):260-271. https://doi.org/10.3747/co.22.2431

Kouroukis, C.T., M. Crump, D. MacDonald, J.F. Larouche, D.A. Stewart, J. Johnston, S. Sauvageau, E. Beausoleil, P. Sage, S.G. Dubois, and et al. 2015. "An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT" Current Oncology 22, no. 4: 260-271. https://doi.org/10.3747/co.22.2431

Kouroukis, C. T., Crump, M., MacDonald, D., Larouche, J. F., Stewart, D. A., Johnston, J., Sauvageau, S., Beausoleil, E., Sage, P., Dubois, S. G., Christofides, A., Di Clemente, S., & Sehn, L. (2015). An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. Current Oncology, 22(4), 260-271. https://doi.org/10.3747/co.22.2431